01—Abstract
Summary
Summary of the 8-K filed May 18, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) completed its acquisition of Soleno Therapeutics, Inc. on May 18, 2026, through a cash tender offer at $53.00a per share followed by a merger under Section 251(h) of the Delaware General Corporation Law, with Soleno becoming a direct, wholly owned subsidiary.
As of the offer expiration at one minute after 11:59 p.m. Eastern time on May 15, 2026, 46,356,114 Soleno shares, representing approximately 88.9% of issued and outstanding shares, had been validly tendered, satisfying the minimum condition. The aggregate cash paid in the offer and merger was approximately $2.9 billionb, plus fees and expenses, funded from Neurocrine's available cash on hand.
Soleno's Soleno Options with exercise prices below the offer price, and Soleno RSU Awards, were cashed out, and Soleno's common stock is no longer listed on the Nasdaq Capital Market. The acquisition adds VYKAT XR (diazoxide choline) extended-release tablets, approved by the FDA on March 26, 2025, for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to Neurocrine's commercial portfolio alongside INGREZZA and CRENESSITY. Neurocrine describes the product as the first and only approved treatment for hyperphagia in Prader-Willi syndrome.
The company also disclosed a new five-year, $1.0 billionc senior secured revolving credit facility dated May 14, 2026, with JPMorgan Chase Bank, N.A. as administrative agent, under which it made an initial borrowing of $600.0 million on the closing date. The credit agreement includes a maximum total net leverage ratio of 3.75:1.00, which may increase to 4.25:1.00 for certain periods following material acquisitions, and a minimum consolidated interest coverage ratio of 2.00:1.00.
Neurocrine granted a security interest in substantially all of its assets, and material domestic subsidiaries will be required to guarantee the obligations. The company has stated it will file the required acquired-business financial statements and pro forma financial information by amendment within 71 calendar days after the initial Form 8-K filing deadline.
02—Key points
Key Highlights
- Acquisition of Soleno Therapeutics completed May 18, 2026 at $53.00 per share in cash, for an aggregate cash payment of approximately $2.9 billion plus fees and expenses.
- 46,356,114 Soleno shares, approximately 88.9% of outstanding shares, were validly tendered by the May 15, 2026 expiration, satisfying the minimum condition.
- Acquisition funded from Neurocrine's available cash on hand.
- Adds VYKAT XR (diazoxide choline), approved March 26, 2025, for hyperphagia in Prader-Willi syndrome patients aged 4 and older, to the commercial portfolio.
- New $1.0 billion five-year senior secured revolving credit facility entered May 14, 2026, with an initial $600.0 million borrowing at closing.
- Credit agreement financial covenants: maximum total net leverage of 3.75:1.00 (up to 4.25:1.00 after certain material acquisitions) and minimum interest coverage of 2.00:1.00.
- Soleno common stock is no longer listed or traded on the Nasdaq Capital Market as of May 18, 2026.
03—Questions
Frequently Asked Questions
How much did Neurocrine pay to acquire Soleno Therapeutics?
Neurocrine paid approximately $2.9 billion in cash for the tender offer and merger, plus related fees and expenses, funded from its available cash on hand. The purchase price was $53.00 per Soleno share.
What product does Neurocrine gain through the acquisition?
Neurocrine gains VYKAT XR (diazoxide choline) extended-release tablets, which the filing describes as the first and only approved treatment for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome. The FDA approved it on March 26, 2025.
How was the acquisition structured?
Neurocrine completed a cash tender offer through a subsidiary, with the offer expiring on May 15, 2026, followed by a merger of the purchaser into Soleno under Section 251(h) of the Delaware General Corporation Law. Soleno continued as a direct, wholly owned subsidiary without any action by Soleno stockholders.
How will Neurocrine finance the transaction and what are the new debt terms?
The filing states the cash came from available cash on hand. Neurocrine also entered a five-year, $1.0 billion senior secured revolving credit facility on May 14, 2026, with an initial $600.0 million drawn at closing. Interest is variable based on Term SOFR plus a margin of 1.125% to 1.75% per annum, or an alternate base rate plus 0.125% to 0.75%, depending on leverage and credit ratings.
What happens to Soleno's outstanding equity awards?
Soleno options with exercise prices below the $53.00 offer price were canceled and converted into cash equal to the spread, while options at or above the offer price were canceled without payment. Soleno RSU awards vested in full and were converted into cash at the offer price. Payments to employees are due within 15 days after the effective time.
04—Continue